Recent advances in artificial intelligence (AI) and telemedicine are transforming healthcare delivery, particularly in rural and underserved communities. Background/Objectives: The purpose of this systematic review is to explore the use of AI-driven diagnostic tools and telemedicine platforms to identify underlying themes (constructs) in the literature across multiple research studies. Method: The research team conducted an extensive review of studies and articles using multiple research databases that aimed to identify consistent themes and patterns across the literature. Results: Five underlying constructs were identified with regard to the utilization of AI and telemedicine on patient diagnosis in rural communities: (1) Challenges/benefits of AI and telemedicine in rural communities, (2) Integration of telemedicine and AI in diagnosis and patient monitoring, (3) Future considerations of AI and telemedicine in rural communities, (4) Application of AI for accurate and early diagnosis of diseases through various digital tools, and (5) Insights into the future directions and potential innovations in AI and telemedicine specifically geared towards enhancing healthcare delivery in rural communities. Conclusions: While AI technologies offer enhanced diagnostic capabilities by processing vast datasets of medical records, imaging, and patient histories, leading to earlier and more accurate diagnoses, telemedicine acts as a bridge between patients in remote areas and specialized healthcare providers, offering timely access to consultations, follow-up care, and chronic disease management. Therefore, the integration of AI with telemedicine allows for real-time decision support, improving clinical outcomes by providing data-driven insights during virtual consultations. However, challenges remain, including ensuring equitable access to these technologies, addressing digital literacy gaps, and managing the ethical implications of AI-driven decisions. Despite these hurdles, AI and telemedicine hold significant promise in reducing healthcare disparities and advancing the quality of care in rural settings, potentially leading to improved long-term health outcomes for underserved populations.

Using an electronic literature search for published articles indexed in PubMed between January 1990 and August 2011, the update of this clinical practice guideline is the result of reviewing 84 clinical trials, 54 reviews, 25 in vitro studies, and 7 evidence-based guidelines. The recommendations below are made following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria: 1: It is recommended that selection of the appropriate aerosol generator and interface be made based on the patient's age, physical and cognitive ability, cost, and the availability of the prescribed drug for use with a specific device. 2: Nebulizers and pressurized metered-dose inhalers (pMDIs) with valved holding chambers are suggested for use with children ≤ 4 years of age and adults who cannot coordinate the use of pMDI or dry-powder inhaler (DPI). 3: It is suggested that administration of aerosols with DPIs be restricted to patients ≥ 4 years of age who can demonstrate sufficient flow for the specific inhaler. 4: For patients who cannot correctly use a mouthpiece, aerosol masks are suggested as the interface of choice. 5: It is suggested that blow-by not be used for aerosol administration. 6: It is suggested that aerosol therapy be administered with a relaxed and nondistressed breathing pattern. 7: Unit dose medications are suggested to reduce the risk of infection. 8: It is suggested that nebulizer/drug combinations should be used as approved by the FDA. 9: It is recommended that healthcare providers know the correct use of aerosol generators; they should teach and periodically re-teach patients about how to use aerosol devices correctly. 10: It is suggested that intermittent positive-pressure breathing should not be used for aerosol therapy. 11: It is recommended that either nebulizer or pMDI can be used for aerosol delivery during noninvasive ventilation.

Introduction: Aerosolized medications are commonly prescribed for the treatment of patients with pulmonary diseases, and there has been an increased interest in the development of aerosol delivery devices over the years. Technical innovations have advanced device design, novel features such as breath actuation, dose tracking, portability, and feedback mechanism during treatment that improved the performance of aerosol devices, and effectiveness of inhalation therapy. Areas covered: The purpose of this paper is to review recent advances in aerosol devices for delivery of inhaled medications. Expert opinion: Drug formulations and device designs are rapidly evolving to make more consistent dosing across a broad range of inspiratory efforts, to maximize dose and target specific areas of the diseased lung.

High-frequency oscillatory ventilation (HFOV) is a lung-protective strategy that can be utilized in the full spectrum of patient populations ranging from neonatal to adults with acute lung injury. HFOV is often utilized as a rescue strategy when conventional mechanical ventilation (CV) has failed. HFOV uses low tidal volumes and constant mean airway pressures in conjunction with high respiratory rates to provide beneficial effects on oxygenation and ventilation, while eliminating the traumatic "inflate-deflate" cycle imposed by CV. Although statistical evidence supporting HFOV is particularly low, potential benefits for its application in many clinical manifestations still remain. High-frequency oscillation is a safe and effective rescue mode of ventilation for the treatment of acute respiratory distress syndrome (ARDS). All patients who have ventilator-induced lung injury (VILI) or are at risk of developing VILI or ARDS would be suitable candidates for HFOV, especially those who have failed conventional mechanical ventilation. This narrative aims to provide a review of HFOV vis-à-vis its indications, contraindications, hazards, parameters to monitoring, patient selection, clinical goals, mechanisms of action, controls for optimizing ventilation and oxygenation, clinical application in ARDS, and a comparison with other modes of mechanical ventilation.